Neurocine’s mid-stage trial drug cuts schizophrenia severity symptoms
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.
An intensifying culture of comparison, that defines success and fulfilment, is behind unrealistic expectations that US parents and kids are forced to chase.
The US Federal Drug Administration approved Illumina Inc.’s DNA sequencing cancer tests that check more than 500 genes in a tumour to help.
The World Health Organization has appealed for $87.4 million over the next six months to stop and contain the current global outbreak of.
McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its.
Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients.
Being popular means being louder. An actor, musician, sportsperson or politician opening up about his or her mental health is better heard than.
A 30-year-old male, who stayed for two weeks in Uganda, has tested positive for mpox in the Central African nation of Gabon, the.
Environmental micro and nanoplastics (MNPs) accumulate in the human brain and total mass concentrations have risen by more than 50% in the past.
Tome Biosciences, a US company engaged in gene editing, will lay off 131 employees as it plans to reduce costs, according to a.